The findings that we report here lead, however, to a different conclusion—that chemerin, acting through CMKLR1, opposes diet-induced obesity and insulin resistance, and that therefore an agonist of CMKLR1 might be of value in the treatment of type 2 diabetes. This evidence concerns the gene CMKLR1 and obesity due to melanocortin 4 receptor deficiency.